Welcome to our dedicated page for Metagenomi Therapeutics news (Ticker: MGX), a resource for investors and traders seeking the latest updates and insights on Metagenomi Therapeutics stock.
Metagenomi Therapeutics, Inc. (Nasdaq: MGX) is a biotechnology company focused on in vivo genome editing and precision genetic medicines. Its news flow centers on progress across its proprietary gene editing toolbox and its therapeutic pipeline, particularly the MGX-001 program for hemophilia A and additional programs in secreted protein deficiencies and cardiometabolic diseases.
News updates for MGX often highlight preclinical data releases, such as non-human primate studies demonstrating durable and therapeutically relevant factor VIII (FVIII) activity for MGX-001, dose range finding results, and safety observations that inform proposed clinical dosing strategies. The company also issues press releases on pipeline prioritization, describing decisions to focus resources on later-stage preclinical assets and its most advanced gene-editing capabilities.
Investors and observers can expect coverage of collaboration milestones, including developments in Metagenomi’s partnership with Ionis Pharmaceuticals on cardiometabolic targets like APOC3. Scientific and medical conference participation is another recurring theme, with the company presenting data at meetings such as the American Society of Gene & Cell Therapy (ASGCT), TIDES USA, and other conferences where it shares advances in compact nucleases, CRISPR-associated transposases (CAST), and AI-guided metagenomic discovery.
MGX news also includes corporate and financial updates, such as quarterly financial results, cash runway commentary, organizational changes, board appointments, and the corporate name change to Metagenomi Therapeutics, Inc. For those following MGX, this news page provides a consolidated view of scientific progress, collaboration updates, and corporate developments reported in press releases and related communications.
Metagenomi, Inc. (Nasdaq: MGX) has regained full control of its gene editing technologies, including base editors and RIGS systems, previously under exclusive rights with Moderna, Inc. The termination of the collaboration on primary hyperoxaluria type 1 (PH1) has allowed Metagenomi to focus on developing therapies for Alpha-1 antitrypsin deficiency and Wilson’s disease, enhancing its strategic flexibility and control. The company aims to accelerate the advancement of its gene editing technologies and engage in target-specific applications through partnerships.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.